GlycoMimetics

GLYC NASDAQ
11.73
-0.15
-1.26%
Opening 11:08 07/19 EDT
Open
11.81
Prev Close
11.88
High
12.14
Low
11.69
Volume
114.99K
Avg Vol (3M)
263.86K
52 Week High
17.78
52 Week Low
8.29
% Turnover
0.27%
Market Cap
506.52M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers GlycoMimetics GLYC stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

GlycoMimetics, Inc. is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate, GMI-1070 (Rivipansel), for the treatment of vaso-occlusive crisis (VOC), a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease. The Company is developing GMI-1271, a specific E-selectin inhibitor, to be used in combination with chemotherapy to treat patients with acute myeloid leukemia (AML), multiple myeloma (MM) and other hematologic cancers. The Company has an additional drug candidate, GMI-1359, that targets both E-selectin and a chemokine receptor, CXCR4. The Company is also advancing other preclinical-stage programs, which include small-molecule glycomimetic compounds that inhibit the proteins galectin-3 and galectin-9.
MORE >

Recently

Name
Price
%Change